PRELIMINARY SCIENTIFIC PROGRAMME

 

 
   
      PLENARY LECTURES
 
Longevity and metabolism
  Johan Auwerx, Lausanne, Switzerland
    
Transplantation: the past, present and the future
  Mohamed H. Sayegh, Beirut, Lebanon
     
Stem cells and pluripotency: mechanisms of reprogramming and gene targeting in ES cells and mice
  George Daley, Cambridge, U.S.A.
   
 
 
MASTERCLASSES
In collaboration with EuroPD
 
Translation of physiology to the clinic
  - PD drug dosing and pharmacokinetics in peritoneal dialysis: neglected but important
    Jan T. Kielstein, Hannover, Germany
  - Fluid management in PD: where is the fluid?
    Jeroen Kooman, Maastricht, The Netherlands
   
Basic science translated from and to PD
  - What can nephrologists learn from fi brosis research in PD?
    Janusz Witowski, Poznan, Poland
  - What can nephrologists learn from infl ammation and immunology research in PD?
    Donald Fraser, Cardiff, United Kingdom
  - Endothelial glycocalix: a new target of research in PD and uraemia related cardiovascular disease?
    Carmen Vlahu, Amsterdam, The Netherlands
 
 
MINI LECTURES
 
Live imaging of the kidney in health and disease
Andrew Hall, Zurich, Switzerland
 
New players in mineral homeostasis
René Bindels, Nijmegen, The Netherlands
 
Angiotensin and tubular salt handling
Laszlo Rosivall, Budapest, Hungary
 
Renal oxygen sensing and EPO
Kai-Uwe Eckardt, Erlangen, Germany
 
Insights into uric acid metabolism from GWAS
Anna Koettgen, Freiburg, Germany
 
Genetic regulation of sodium and potassium transport through WNK kinases
Xavier Jeunemaitre, Paris, France
 
New insights on calcium disorders
Rajesh V. Thakker, Oxford, United Kingdom
 
Autosomal dominant polycystic kidney disease: new insights into treatment
Imed Helal, Tunis, Tunisia
 
The JAK /STAT pathway in renal diseases
Jesus Egido, Madrid, Spain
 
Vascular and endothelial dysfunction in pre-eclampsia
Kate Bramham, London, United Kingdom
 
Pulmonary-renal syndrome
Charles Pusey, London, United Kingdom
 
Peritoneal dialysis in the management of AKI: has it been ignored?
Daniela Ponce, Botucatu, Brazil
 
Oliguria as a marker of AKI
Wim Van Biesen, Ghent, Belgium
 
AKI as a side effect of cancer therapy
Sylvie Rottey, Ghent, Belgium
 
Cross-fertilization between the ERA-EDTA registry and national registries
Benedicte Stengel, Villejuif, France
 
Where do all these CKD Stage 3 patients disappear and do not progress to CKD 4
Mustafa Arici, Ankara, Turkey
 
Diabetic nephropathy - from the registry to clinical management
Ivan Rychlik, Prague, Czech Republic
 
History of the laboratory diagnosis of renal disease
Athanasios Diamandopoulos, Patras, Greece
 
Immunization against high blood pressure - an update
Tomasz Guzik, Glasgow, United Kingdom
 
Does renal denervation infl uence the progression on CKD? Con
Dagmara Hering, Perth, Austrialia
 
Does renal denervation infl uence the progression on CKD? Pro
Peter J. Blankestijn, Utrecht, The Netherlands
 
Protein-bound uremic toxins stimulate crosstalk between leukocytes and vessel wall
Anneleen Pletinck, Ghent, Belgium
 
Volume - Na - impedance
Adrian Covic, Iasi, Romania
 
The relationship between endothelial dysfunction and cardiovascular disease in CKD
Mahmut Ilker Yilmaz, Ankara, Turkey
 
Sodium intake: what is right for people with CKD
Johannes F.E. Mann, Munchen, Germany
 
State of the art of the wearable artificial kidney
Claudio Ronco, Vicenza, Italy
 
Klotho is a key player in cardiovascular risk during dialysis
Denis Fouque, Lyon, France
 
Exercise on haemodialysis
Halima Resic, Sarajevo, Bosnia and Herzegovina
 
Needling strategies and management
Ramon Roca-Tey, Barcelona, Spain
 
The infl amed uremic phenotype - a mediator of premature aging
Peter Stenvinkel, Stockholm, Sweden
 
Important trials in transplantation in the last 12 months
Bruno Watschinger, Vienna, Austria
 
Post transplantation diabetes mellitus – novel pathogenetic factors and therapeutic recommendations
Mads Hornum, Copenhagen, Denmark
 
 
SYMPOSIA
 
Special Symposia
 
ERA-EDTA Registry
  -

Why do girls with end-stage renal disease wait longer for transplantation than boys?

  - Julien Hogan, La Plaine Saint-Denis, France
  -

EURODOPPS

  -

Fergus Caskey, Bristol, United Kingdom

  -

Racial disparities in the access to and outcomes of paediatric RRT

  -

Lidwien Tjaden, Amsterdam, The Netherlands

  -

Trends in the epidemiology of renal replacement therapy

  -

Maria Pippias, Amsterdam, The Netherlands

  -

Stage 4 CKD - first results of the EQUAL study

  -

Moniek Van De Luijtgaarden, Amsterdam, The Netherlands

     
Young Nephrologists’ Platform (YNP) - Tomorrow’s nephrology presented by the nephrologists of tomorrow
  - Overview on past and future initiatives of the YNP
    Miklos Z. Molnar, Memphis, U.S.A.
  - Innate and adaptive immunity and the kidney: a pathfi nder tale
    Kathrin Eller, Graz, Austria
  - The nephrologist of tomorrow - towards a kidney-omic future?
    Francesco Pesce, London, United Kingdom
  - Emerging factors for predicting adverse outcomes in kidney transplantation: more pieces to the puzzle?
    Maarten Naesens, Leuven, Belgium
     
Late Breaking Clinical Trials
   
The Lancet
   
Hot ethical issues in modern nephrology
  - When to stop or not to stop renal replacement: do ethic rules offer guidance?
  - Ethical dilemmas in living kidney donation (psychical pressure; bribery)
  - How chronic kidney diseases differ from other chronic diseases from ethical point of view?
  - Ethics and economics of rare diseases
     
International Practices and Improved Dialysis Outcomes: The DOPPS Program
  - The DOPPS program continues to grow - special highlights
    Ron Pisoni, Ann Arbor, U.S.A.
  - EURODOPPS: First birthday
    Kitty Jager, Amsterdam, The Netherlands
  - CKDopps: Improving outcomes in advanced CKD and the transition to dialysis
    Werner Kleophas, Düsseldorf, Germany
  - PDOPPS as a unique opportunity for ancillary research: plans for the UK PD catheter study
    Martin Wilkie, Sheffield, United Kingdo
  - Measuring the patient experience: a useful approach to improve dialysis care?
    Hugh Rayner, Birmingham, United Kingdom
    Panel Discussion
     
What is new and hot in paediatric nephrology: report of ESPN Working Groups activity
  - Adults and children with renal diseases: a common working area for ESPN and ERA-EDTA
    Rosanna Coppo, Turin, Italy
  - CKD mineral and bone disorder WG
    Dieter Haffner, Hannover, Germany
  - ESPN WG CAKUT/UTI/Bladder dysfunction: news and activities
    Stefanie Weber, Essen, Germany
  - Idiopathic nephrotic syndrome WG
    Georges Deschenes, Paris, France
     
ASN Highlights
  - Acute Kidney Injury
    Ravindra L. Mehta, San Diego, USA
  - Hypertension
    Aldo Peixoto, New Haven, USA
  -  General Nephrology/CKD
     Michel Chonchol, Denver, USA
     
SYSKID - Prognosis and therapy of diabetic nephropathy: one size does not fit them all
  - The epidemiology of CKD in Europe: implications for healthcare policies
    Kitty J. Jager, Amsterdam, The Netherlands
  - Clinical utility of risk scores/biomarkers to predict progression and outcome in diabetic nephropathy
    Peter Rossing, Gentofte, Denmark
  - Linking biomarkers to pathophysiology and treatment response: a systems biology approach
    Bernd Mayer, Vienna, Austria
  - Enrichment strategies in clinical trials - the road to personalized medicine in nephrology?
    Dick De Zeeuw, Groningen, The Netherlands
     
ERA-EDTA & CSN (Chinese Society of Nephrology) Joint Symposium
  - Diabetic nephropathy: a growing challenge in China
    Chuan Ming Hao, Shanghai, China
  - Diabetic nephropathy in Europe
    Carl-Erik Mogensen, Aarhus, Denmark
  - Management of amyloidosis in China
    Xiang Hua Huang, Nanjing, China
  - Amyloidosis in Europe
    Speaker to be confirmed
   
ERA-EDTA & JSN Joint Symposium
  - Past, present, future: continuous challenge against kidney disease
    Seiichi Matsuo, Nagoya, Japan
  - Development of novel drugs targeting CKD: hypoxia, oxidative stress, and epigenetic
    Masaomi Nangaku, Tokyo, Japan
  - Treatment practice in patients with CKD: results from the GCKD study
    Kai-Uwe Eckardt, Erlangen, Germany
  - CKJ - translational research
    Alberto Ortiz, Madrid, Spain
   

Valvular heart disease in renal failure patients - Joint symposium ERA-EDTA & ESC

  - Natural history of aortic stenosis in renal insufficiency patients
    Raphael Rosenhek, Vienna, Austria
  - TAVI procedure in renal insufficiency patients
    Speaker to be confirmed
  - Valvular calcification in CKD patients
    Antonio Bellasi, Como, Italy
  - The problem of anticoagulation in CKD patients with valvular disease
    Jürgen Floege, Aachen, Germany
     
NDT Pearls and Polar Views
   -  Clinical science pearls in Nephrology Dialysis and Transplantation in 2013-2014
    Carmine Zoccali, Reggio Calabria, Italy
     
 

NDT Polar Views

 

ABPM for the diagnosis and the monitoring of hypertension in dialysis patients

  - ABPM should be systematically applied in dialysis patients
   

Rajiv Agarwal, Indianapolis, USA

  - ABPM should be applied only when really needed to make diagnostic or therapeutic decisions
   

Alan Jardine, Glasgow, UK

       
ERA EDTA & ESH (European Society of Hypertension) Joint Symposium
  -

Multidisciplinary approach of adherence in hypertensive renal patients

   

Michel Burnier, Lausanne, Switzerland

  -

Ambulatory blood pressure monitoring – the neglected child in nephrology

   

Josep Redon, Valencia, Spain

  -

Bioimpedance-derived volume assessment for all hypertensives

   

David Goldsmith, London, United Kingdom

  -

Aldosterone blockade vs. dual renin-angiotensin blockade in patients with resistant hypertension

   

Speaker to be confirmed

        
ISN Session: addressing the global unmet needs for AKI
  - Introduction: ISN AKI 0by25: a human rights case for nephrologists
   

Giuseppe Remuzzi, Bergamo, Italy

  - The burden of AKI throughout the world: existing data
   

Norbert Lameire, Ghent, Belgium

  - The Global Snapshot: results of a groundbreaking study on AKI
   

Ravindra L. Mehta, San Diego, USA

  - Strategies to avoid preventable deaths from AKI in low/middle income countries
   

Andrew Lewington, Leeds, UK

 
Track 1
Fluid and electrolytes, tubular transport, physiology
 
Acid-base regulation and the kidney
  - Alkali therapy to slow down progression of CKD
    Thomas H. Hostetter, Cleveland, U.S.A.
  - New insights into acid-base regulation and the kidney
    Dominique Eladari, Paris, France
  - Pathophysiology and clinical diagnosis of distal renal tubular acidosis
    Robert Unwin, London, United Kingdom
  - The genetics of acid-base disorders
    Fiona Karet, Cambridge, United Kingdom
 
New insights into phosphate handling by kidney, bone and vasculature
  - Renal handling of phosphate
    Carsten Wagner, Zurich, Switzerland
  - FGF23 regulation in bone and kidney
    Klaus Olgaard, Copenhagen, Denmark
  - Bone and vasculature crosstalk in health and disease
    Gérard London, Fleury-Merogis, France
  - The role of FGF23 and Klotho in CKD
    Justine Bacchetta, Bron, France
 
Channels and transporters: new drug targets
  - Inhibition of SGLT glucose transporters
    Volker Vallon, San Diego, U.S.A.
  - Calcium-sensing and regulation of tubular transport
    Pascal Houillier, Paris, France
  - Targeting the vasopressin-aquaporin axis
    Peter Deen, Nijmegen, The Netherlands
  - Targeting the water channel AQP1
    Olivier Devuyst, Zurich, Switzerland
 
Mechanisms and effects of renal remodelling and ageing
  - Glomerular epithelial cells in ageing and disease
    Marcus J. Moeller, Aachen, Germany
  - Ion transport and epithelial remodelling in the renal distal tubule
    Johannes Loffing, Zurich, Switzerland
  - The renin-angiotensin-aldosterone system and the ageing kidney
    Ariela Benigni, Bergamo, Italy
  - Epithelial-mesenchymal transition (EMT) in kidney fi brosis: fact or fantasy?
    Alberto Ortiz, Madrid, Spain
 
Track 2
Hereditary disorders, development, pregnancy, paediatric nephrology
 
Storage and traffic disorders The Renal Association
  - Overview of renal storage disorders
    Luca Rampoldi, Milan, Italy
  - Cystinosis
   

William Van’t Hoff, London, United Kingdom

  - New insights into lysosomal storage disorders
    Carmine Settembre, Naples, Italy
  - Renal Fanconi syndromes
    Robert Kleta, London, United Kingdom
 
ADPKD
  - ADPKD: emerging mechanisms in disease pathogenesis
    Albert Ong, Sheffield, United Kingdom
  - ADPKD: clinical studies in China
    Chang Lin Mei, Shanghai, P.R. China
  - ADPKD: the HALT studies
    Arlene B. Chapman, Atlanta, U.S.A.
  - Genetic testing in ADPKD: assessing clinical utility
    Richard N. Sandford, Cambridge, United Kingdom
 
From kidney development to kidney regeneration: deciphering developmental cues to engineer kidneys
  - From human pluripotent stem cells to early nephron
    Kenji Osafune, Kyoto, Japan
  - From pluripotent stem cells to early collecting system
    Juan Carlos Izpisua Belmonte, La Jolla, U.S.A.
  - Utilization of human nephron stem cells to repair broken kidneys
    Benjamin Dekel, Ramat Gan, Israel
  - Renal progenitor cells: a strategy for kidney regeneration
    Paola Romagnani, Florence, Italy
 
Growth in pediatric kidney disease
  - Clinical and epidemiological aspects
    George S. Reusz, Budapest, Hungary
  - Growth as the best clinical endpoint to assess CKD-MBD in children?
    Justine Bacchetta, Bron, France
  - Bone and growth biomarkers in 2015
    Dieter Haffner, Hannover, Germany
  - Growth hormone therapy after two decades of practice
    Lesley Rees, London, United Kingdom
 
Haemolytic Uremic Syndrome - a complement disorder The Renal Association
  - The role of complement in endothelial activation
    Anna Richards, Stevenage, United Kingdom
  - Atypical HUS genetics and treatment
    Tim Goodship, Newcastle Upon Tyne, United Kingdom
  - The glomerular response to shigatoxin in the pathogenesis of D+ HUS
    Moin Saleem, Bristol, United Kingdom
  - From mutations in complement genes to clinical use of eculizumab
    Véronique Frémeaux-Bacchi, Paris, France
 
Track 3
Glomerular diseases and general clinical nephrology
 
B-cell targeted treatment in glomerular disease The Renal Association
  - B-cell targeting in ANCA-associated vasculitis
    David Jayne, Cambridge, United Kingdom
  - B cell targeteting in lupus nephritis
    Liz Lightstone, London, United Kingdom
  - B cell targeting in membranous nephropathy
    Piero Ruggenenti, Bergamo, Italy
  - B cell targeting in minimal change disease and FSGS
    Annette Bruchfeld, Stockholm, Sweden
 
IgA nephropathy
  - Genetics studies of IgAN reveal links to mucosal pathogens
    Ali G. Gharavi, New York, U.S.A.
  - Modifiable and unmodifiable risk factors for progression of IgA nephropathy
    Rosanna Coppo, Turin, Italy
  - The role of micro-RNA in IgA nephropathy
    Francesco Paolo Schena, Bari, Italy
  - Formation of IgA deposits in Berger’s disease: what we learned from animal models
    Renato Monteiro, Paris, France
 
Everyday questions from the glomerulonephritis clinic
  - Managing thrombotic risk in nephrotic syndrome
    Vladimir Tesar, Prague, Czech Republic
  - Approach to the patient with HIV infection referred with proteinuria
    Jeremy Levy, London, United Kingdom
  - Which patients with IgA nephropathy benefit from immunotherapy?
    Jürgen Floege, Aachen, Germany
  - Which patients with diabetes and proteinuria need renal biopsy?
    Loreto Gesualdo, Altamura, Italy
 
Novel therapeutic approaches in glomerular diseases
  - Biomarker-guided personalized treatment of proteinuria
    Peter Mundel, Boston, U.S.A.
  - Complement targeted therapies in glomerular diseases
    Giuseppe Remuzzi, Bergamo, Italy
  - Current management of lupus nephritis
    Frédéric A. Houssiau, Brussels, Belgium
  - IL-17 as a therapeutic target in crescentic glomerulonephritis
    Ulf Panzer, Hamburg, Germany
 
New aspects of podocyte diseases/podocyte stress
  - The challenge and response of podocytes to glomerular hypertension
    Nicole Endlich, Greifswald, Germany
  - The role of mechanical forces in podocyte injury
    Wilhelm Kriz, Mannheim, Germany
  - Ischemic injury of podocyte as a cause of collapsing glomerulopathy
    Surya V. Seshan, New York, U.S.A.
  - Molecular and genetic basis of inherited nephrotic syndrome
    Maddalena Gigante, Foggia, Italy
 
Track 4
Acute kidney injury and intensive care nephrology
 
AKI: general concepts / definition / validation / implementation The Renal Association
  - The health economic burden of AKI
    Donal O’Donoghue, Salford, United Kingdom
  - AKI detection and early intervention: the role of e-alerts
    Mark Devonald, Nottingham, United Kingdom
  - AKI: a true risk or predictor of CKD?
    Paul Stevens, Canterbury, United Kingdom
  - Novel treatments in AKI
    Andrew Lewington, Leeds, United Kingdom
 
How to avoid / treat AKI: What do we know? What do we hope?
  - Prevention of AKI, which fluid?
    Donal Reddan, Galway, Ireland
  - Are there differences in the prevention of AKI between younger and older individuals?
    Norbert H. Lameire, Landegem, Belgium
  - Mechanisms of repair after acute kidney injury
    Joseph V. Bonventre, Boston, U.S.A.
 
Biomarkers
  - Uremic toxin profile in AKI versus CKD: any therapeutic implications?
    Raymond Vanholder, Ghent, Belgium
  - NGAL vs KIM-1 vs other biomarkers
    Orfeas Liangos, Coburg, Germany
  - The use of biomarkers in septic AKI
    Jill Vanmassenhove, Ghent, Belgium
 
RRT and AKI
  - Intermittent haemodialysis and isolated ultrafiltration
    Christophe Vinsonneau, Melun, France
  - Renal replacement therapy in the emerging world
    Valerie A. Luyckx, Zurich, Switzerland
  - Individualing hemodialysate in various types of AKI
    Francesco Locatelli, Lecco, Italy
  - Should indications be uniform to start RRT in all types of AKI?
    Mehmet Sukru Sever, Istanbul, Turkey
      
Track 5
CKD - epidemiology, prevention, progression, pathophysiology, aging
          
 
Patient satisfaction
  - Patient satisfaction: why and how measure it in dialysis patient?
    Serge Briançon, Nancy, France
  - An overview of instruments to measure satisfaction with care in patients on renal replacement therapy
    Sabine Van Der Veer, Manchester, United Kingdom
  - How to implement patient satisfaction in practice patterns evaluation?
    Luc Frimat, Nancy, France
  - Is patient satisfaction a concept that is acceptable in a developing country?
    Fayçal Jarraya, Sfax, Tunisia
 
Aging kidney
  - Is there a link between foetal programming and the aging kidney?
    Kerstin Amann, Erlangen, Germany
  - Estimating GFR in the elderly in 2014
    Christophe Mariat, Saint-Etienne, France
  - Age and association of kidney measures with mortality and end-stage kidney disease
    Stein I. Hallan, San Diego, U.S.A.
  - Impact of socioeconomic conditions on elderly CKD
    Andrzej Wiecek, Katowice, Poland
 
Proteinuria: therapies beyond renin-angiotensin inhibition
  - Endothelin Receptor Antagonists to lower proteinuria: looking beyond RAAS intervention
    Hiddo J Lambers Heerspink, Groningen, The Netherlands
  - Can we heal the actin cytoskeleton?
    Mario Schiffer, Hannover, Germany
  - T-type calcium channel inhibitors and proteinuria: a potential renal therapy
    Bruce Hendry, London, United Kingdom
  - Insulin and podocytes
    Richard Coward, Bristol, United Kingdom
 
Uremic toxicities
  - Uremic toxins and cardiovascular outcomes
    Roberto Pecoits-Filho, Curitiba, Brazil
  - Uremic toxins and renal outcomes
    Griet Glorieux, Ghent, Belgium
  - Uremic toxins and neurological outcomes
    Jean-Marc Chillon, Amiens, France
  - Uremic toxins and gut
    Pieter Evenepoel, Leuven, Belgium
 
Track 6
Hypertension, diabetes, vascular disease
 
Diabetes, blood pressure and kidney disease
  - Emerging molecular footprints of diabetic kidney injury
    Tobias Huber, Freiburg, Germany
  - Divergent pathophysiology/clinical course of nephropathy in type 1 and type 2 diabetes
    Paola Fioretto, Padua, Italy
  - Albuminuria in diabetic patients: prognosis and management
    Michel Jadoul, Brussels, Belgium
  - New treatment options to retard progression in CKD patients with diabetes
    Luigi Gnudi, London, United Kingdom
 
Lipoproteins in CKD revisited
  - Dyslipidaemia in CKD: a risk factor for CV disease and CKD progression?
    David Wheeler, London, United Kingdom
  - Current guidelines and treatment strategies for dyslipidemia in CKD
    Christoph Wanner, Würzburg, Germany
  - Modifi cations of HDL in chronic kidney disease and their clinical relevance
    Marcus Saemann, Vienna, Austria
  - Lipoproteins, immune system and vascular disease in CKD
    Thimoteus Speer, Homburg/Saar, Germany
 
Renovascular hypertension – when and whom to offer revascularisation?
  - Current diagnostic algorithms in patients with renal artery stenosis
    Andrzej Januszewicz, Warsaw, Poland
  - Life after ASTRAL and CORAL: where do we go now with renal revascularization for atherosclerotic renal artery stenosis?
    Philip A. Kalra, Salford, United Kingdom
  - Fibromuscular dysplasia - current epidemiology and treatment
    Pierre-Franςois Plouin, Paris, France
  - Cardiovascular complications in patients with renovascular hypertension
    Roland E. Schmieder, Erlangen, Germany
 
Obesity and the kidney
  - ORG (Obesity Related Glomerulopathy) - does it exist?
    Esteban Porrini, La Laguna, Spain
  - State of the art in weight management
    Hermann Toplak, Graz, Austria
  - Obesity-associated arterial hypertension
    Jens Jordan, Hanover, Germany
  - Renoprotection in obese patient
    Francesca Mallamaci, Reggio Calabria, Italy
 
Vitamin D deficiency in CKD patients
  - Epidemiology of hypovitaminosis D in CKD patients
    Michal Nowicki, Lodz, Poland
  - Hypovitaminosis D and cardiovascular disease in CKD
    Markus Ketteler, Coburg, Germany
  - Vitamin D, FGF 23 and Klotho - an important triangle in CKD patients
    Danilo Fliser, Homburg/Saar, Germany
  - Treatment with vitamin D – to whom, what and when?
    David Goldsmith, London, United Kingdom
 
Track 7
End stage renal disease, dialysis, peritoneal dialysis
 
CKD-MBD: update 2015
  - New biomarkers in CKD-MBD
    Marc Vervloet, Amsterdam, The Netherlands
  - The calcium-phosphate product and FGF23
    Pablo Antonio Ureña Torres, Saint-Ouen, France
  - Phosphate binders: which next?
    Tilman Drueke, Amiens, France
  - Which Vitamin D in dialysis patients?
    Mario Cozzolino, Milan, Italy
 
Vascular calcification: what’s new?
  - Mechanisms of vascular calcification in CKD-evidence for premature ageing?
    Ziad Massy, Paris, France
  - The vitamin D system and the vasculature
    Sandro Mazzaferro, Rome, Italy
  - Should we check for VC in all CKD patients?
    Jordi Bover, Barcelona, Spain
  - Vitamin K: key vitamin in controlling vascular calcification in chronic kidney disease
    Vincent Brandenburg, Aachen, Germany
 
Hypercoagulability in ESRD: Myth or reality?
  - Underlying causes
    Jolanta Malyszko, Bialystok, Poland
  - Risk groups and anticoagulation
    Jens Lutz, Mainz, Germany
  - Pulmonary embolism in chronic kidney disease: a lethal but overlooked disease
    Gürbey Ocak, Utrecht, The Netherlands
  - Vascular access in patients with hypercoagulability
    Andrew Davenport, London, United Kingdom
 
Inflammation in CKD and dialysis patients
  - Monitoring infl ammation in patients on dialysis: why, how, and what else?
    Christian Combe, Bordeaux, France
  - Uremic toxins, infl ammation and perturbation of glucose metabolism
    Laetitia Koppe, Montreal, Canada
  - Any relationship between systemic and peritoneal inflammation?
    Sylvie Opatrná, Pilsen, Czech Republic
  - Is EMT of the mesothelium related to an inherent or acquired fast peritoneal transport status and ultrafiltration failure?
    Rafael Selgas, Madrid, Spain
 
Dialysis in the elderly
  - End-of-life and palliative care in the dialysis setting
    Ken Farrington, Stevenage, United Kingdom
  - Assessing functional status
    Eva Topinkova, Prague, Czech Republic
  - Nutritional characteristics in the elderly dialysis patients
    Daniel Teta, Lausanne, Switzerland
  - The best peritoneal dialysis program for elderly patients
    Olof Heimbürger, Stockholm, Sweden
 
New osmotic agents
  - Carnitine
    Mario Bonomini, Chieti, Italy
  - GLAD
    Raymond T. Krediet, Amsterdam, The Netherlands
  - Hyperbranched polyglycerol
    Asher Mendelson, London, Canada
  - Glucose polymers
    John Leypoldt, Deerfield, U.S.A.
 
Personalised care and dialysis
  - Extended-hours hemodialysis: benefits and barriers
    Charles Chazot, Sainte Foy Les Lyon, France
  - Is thrice weekly dialysis adequate for all ESRD patients?
    Ercan Ok, Izmir, Turkey
  - Conservative treatment
    Fergus Caskey, Bristol, United Kingdom
  - Management of advanced CKD in the elderly
    Steven J. Rosansky, Columbia, U.S.A.
 
Track 8
Transplantation
 
HLA and non-HLA Antibodies - Avoid them or treat them?
  - Non-HLA Antibodies - ready to enter the clinic arena?
    Magali Giral, Nantes, France
  - What is the best HLA-desensitisation protocol with regard to long term outcomes?
    Ondrej Viklicky, Prague, Czech Republic
  - Post-transplant DSA – ignore, follow, treat?
    Thomas Fehr, Zurich, Switzerland
  - Kidney exchange and domino-paired transplantation
    Willem Weimar, Rotterdam, The Netherlands
 
Viruses: transplantation in the light of new treatment options
  - Management of kidney transplant patient with chronic hepatitis C infection
    Petar Kes, Zagreb, Croatia
  - HBV and kidney transplant patients
    Fabrizio Fabrizi, Milan, Italy
  - Treatment of HEV infection after transplantation
    Nassim Kamar, Toulouse, France
  - Update on vaccines for transplant candidates and recipients
    Martina Sester, Homburg/Saar, Germany
 
Age dependent problems in transplantation
  - Organ age and immune responses
    Marian Klinger, Wroclaw, Poland
  - Transplantation in old recipients: what are the challenges?
    Julio Pascual, Barcelona, Spain
  - Psycho-social problems and adherence in adolescent kidney transplant recipients
    Istvan Mucsi, Toronto, Canada
 
Disease recurrence – are there new treatment strategies on the horizon?
  - Recurrence of atypical HUS, TMA post renal transplantation
    Moglie Donnette-Le Quintrec, Paris, France
  - Recurrent Focal Glomerulosclerosis
    Paolo Cravedi, New York, U.S.A.
  - Kidney transplantation in primary hyperoxaluria type 1
    Pierre Cochat, Bron, France
 
 
CME COURSES
   

Thursday, 28 May - 09:00-12:15
 

CME 1 – EURECA-m Working Group
 

Updates in cardiorenal cross-talks
 

Hypertension, leukocytes and vascular disease
Carotid barostimulation in resistant hypertension
Patrick Rossignol, Vandoeuvre-Les-Nancy, France
Cross talk between leukocytes and vessel wall as a source of vascular damage in uremia
Raymond Vanholder, Ghent, Belgium
A new auto-immune disease: hypertension
Mehmet Kanbay, Istanbul, Turkey

CKD-MBD, adipokines and vascular disease
FGF-23: innocent bystander or causative factor in CKD-associated cardiovascular disease?
Gunnar Heine, Homburg/Saar, Germany
The bone-vascular cross-talk and CKD progression: FGF23 and ADMA interaction
Carmine Zoccali, Reggio Calabria, Italy
Role of adipokines in cardiovascular complications in CKD patients – new evidence
Andrzej J. Wiecek, Katowice, Poland


Thursday, 28 May - 09:00-12:15
 

CME 2 - CKD-MBD Working Group
 

An update on Mineral and Bone Disordes in CKD
 

Introduction
Mario Cozzolino, Milano, Italy

First session
Evolving insights into the regulation of FGF23 and Klotho
Marc Vervloet, Amsterdam, The Netherlands
New Biomarkers in CKD-MBD
Sandro Mazzaferro, Rome, Italy
Calciphylaxis - the power of the dark calcification side
Vincent Brandenburg, Aachen, Germany
Discussion
 

Second session
CaSR in CKD
Ziad Massy, Paris, France
To D or not to D in CKD - is VD treatment unavoidable?
David Goldsmith, London, United Kingdom
Discussion

Third session
Adynamic Bone Disease: from bone to disease
Jordi Bover, Barcelona, Spain
Indications of bone biopsy in CKD
Pablo Antonio Ureña Torres, Saint-Ouen, France
Closing remarks
Mario Cozzolino, Milano, Italy
Discussion


Thursday, 28 May - 09:00-12:15
    
CME 3 – DESCARTES Working Group - In collaboration with EKITA (*)
(*) EKITA is a Section of ESOT

   

Tolerance, minimization, and living donation in 2015
  

The race between tolerance and minimization strategies
The genetic determinants of acute rejection
Marc Abramowicz, Brussels, Belgium
The genetic determinants of tolerance
Speaker to be confirmed
To what extent can CNI be minimized?
Klemens Budde, Berlin, Germany
Who needs anti-lymphocyte induction therapy in 2015?
Daniel Abramowicz, Antwerp, Belgium
  

Hurdles of living-donor kidney transplantation
What is the risk of dialysis or death after living donation?
Umberto Maggiore, Parma, Italy
The long road to living donor selection
Søren Schwartz Sørensen, Copenhagen, Denmark
The long road to recipient wait-listing
Speaker to be confirmed
Living kidney donation: future studies
Geir Mjøen, Oslo, Norway


Thursday, 28 May - 09:00-12:15
 

CME 4 – Immunonephrology Working Group
 

Immune mediated renal diseases: news from the ERA-EDTA IWG
 

Autoantibodies for diagnosis and prognosis of glomerular diseases
Anti-PLA2R antibodies in membranous nephropathy
Elion Hoxha, Hamburg, Germany
New and old auto antibodies in Lupus Nephritis
Vladimir Tesar, Prague, Czech Republic
ANCA in vasculitis new perspectives
Mårten Segelmark, Linköping, Sweden
Anti-complement antibodies in MPGN/C3 nephropathy
Marina Noris, Bergamo, Italy

Clinical endpoints for clinical trials: toward a position paper
IgA Nephropathy in the young
Rosanna Coppo, Turin, Italy
IgA Nephropathy in the adult
Jürgen Floege, Aachen, Germany
Lupus Nephritis
David Jayne, Cambridge, United Kingdom
Membranous nephropathy
Jack F.M. Wetzels, Nijmegen, The Netherlands


Thursday, 28 May - 09:00-12:15
 

CME 5 - EUDIAL Working Group
 

The rationale for high volume haemodiafiltration
 

Why do we need convective clearance and different treatment options
Speaker to be confirmed
High volume haemodiafiltration in clinical practice
Muriel P. Grooteman, Amsterdam, The Netherlands
Clinical outcomes with HDF
Speaker to be confirmed

Providing high volume haemodiafiltration in clinical practice
Maintaining water quality for HDF - how much testing is required?
Elizabeth Lindley, Leeds, United Kingdom
Why should higher volume HDF improve patient survival?
Francesco Locatelli, Lecco, Italy
Is HDF a more expensive treatment compared to other modalities?
Antonio Santoro, Bologna, Italy


Thursday, 28 May - 09:00-12:15
 

CME 6 - DIABESITY Working Group
 

DIABESITY: Diabetes, Obesity and Renal Disease
 

Connection between obesity, type 2 diabetes and renal disease
Bjørn Richelsen, Aarhus, Denmark
Obesity: a risk factor for renal disease, evidence from clinical studies
Manuel Praga, Madrid, Spain
Diabetes, obesity and renal disease: lessons from recent clinical trials
Speaker to be confirmed
The role of carnosine metabolism in CKD in patients with type-2 diabetes
Speaker to be confirmed
New markers of renal disease in obesity and diabetes
Radovan Hojs, Maribor, Slovenia
Regression of renal lesions in diabetic and non diabetic renal diseases
Giuseppe Remuzzi, Bergamo, Italy


Thursday, 28 May - 09:00-12:15
 

CME 7 – EUTox Working group
 

Uremic toxicity: the compounds and how to clear them
 

Part I
Redefining uremic retention solutes and uremic toxins: a novel conceptual framework with therapeutic implications
Speaker to be confirmed
Aryl hydrocarbon receptor, a new signaling pathway activated by uremia
Stéphane Burtey, Marseille, France
Endothelial microparticles and vascular calcification
J. Mariano Rodriguez, Cordoba, Spain
 

Part II
Dialysis procedures and artificial toxicity in uraemic patients
Bernd Stegmayr, Umea, Sweden
Enhancing dialysis efficacy: dissociating protein-bound uremic retention solutes to increase clearance
Speaker to be confirmed
Enhancing dialysis efficacy: modifying pore size and physics to increase removal
Speaker to be confirmed


Thursday, 28 May - 09:00-12:15
 

CME 8 – Working Group on Inherited Kidney Disorders
 

An update on Inherited Kidney Disorders
 

Genetic diseases of tubular potassium transport
Detlef Bockenhauer, London, United Kingdom
Autosomal Dominant Tubulointerstitial Kidney Disease
Olivier Devuyst, Zurich, Switzerland
Clinical trials in ADPKD: where we are and where we go from here
Ron T. Gansevoort, Groningen, The Netherlands
Complement-mediated glomerular injury: lessons from animal models
Katherine Vernon, London, United Kingdom
Steroid resistant nephrotic syndrome: lessons from the Podonet registry
Franz Schaefer, Heidelberg, Germany
Proteomic and metabolomics analyses in kidney diseases
Robert Unwin, London, United Kingdom


Thursday, 28 May - 13:15-15:15
 

CME 9 - EuroPD Working Group
 

Basic clinical CME
 

Physiology and pathophysiology of peritoneal membrane transport
Anabela Rodrigues, Porto, Portugal
Peritoneal membrane testing and adequate prescription of peritoneal dialysis regimens in clinical practice
Miguel Perez Fontan, La Coruña, Spain
Outcomes on PD: lessons from different cohort and registry studies
Speaker to be confirmed
Framing information during pre-dialysis education: actively supporting patients’ decision-making
Hilary Bekker, Leeds, United Kingdom


Thursday, 28 May - 13:15-15:15
 

CME 10
 

Rheumatology for nephrologists
 

Diagnostic approach to the CKD patient with joint pain
Hans-Joachim Anders, Munich, Germany
Diagnosis and treatment of gout in CKD patients
Speaker to be confirmed
What do nephrologists need to know about the auto-inflammatory disorders?
Helen Lachmann, London, United Kingdom
Takayasu arteritis and the kidney
Justin Mason, London, United Kingdom
Why drug monitoring in lupus nephritis
Nathalie Costedoat-Chalumeau, Paris, France
The dilemma: Disease activity in lupus nephritis
Philipp Enghard, Berlin, Germany


Thursday, 28 May - 13:15-15:15
 

CME 11
 

ERBP
 

Asking the right questions: the guideline on the frail and elderly example
Evi Nagler, Ghent, Belgium
Considering the right outcomes: on hyponatraemia and calcimimetics
Ionut Nistor, Iasi, Romania
Rare disease? Challenging guideline!
Davide Bolignano, Reggio Calabria, Italy
Get the guideline to work: the diabetes guideline example
Sabine Van Der Veer, Manchester, United Kingdom
How systematic is systematic: the vascular access guideline
Speaker to be confirmed
Did you read the guideline?
Wim Van Biesen, Ghent, Belgium


Thursday, 28 May - 13:15-16:15
 

CME 12
 

Cross-talk in Renal Epidemiology
 

First part
Selection bias in renal research
Carmine Zoccali, Reggio Calabria, Italy
Missing data
Speaker to be confirmed
Linkage to achieve big data
Speaker to be confirmed
 

Second part
IV analysis
Friedo W. Dekker, Leiden, The Netherlands
Using propensity scores to adjust for confounding in medical research
Stijn Vansteelandt, Ghent, Belgium


Thursday, 28 May - 13:15-15:15
 

CME 13 – European Renal Nutrition (ERN) Working Group
 

Do renal diseases need a Nutrition Working Group?
 

Nutritional disorders: also after kidney transplantation
Pieter M. Ter Wee, Amsterdam, The Netherlands
Practical screening and assessment of nutritional status in CKD: what, when and by whom?
Lina Johansson, London, United Kingdom
The conundrum of salt and protein intake in renal progression
Vincenzo Bellizzi, Salerno, Italy
Controlling metabolic acidosis with a healthy diet in CKD patients: feasible?
Philippe Chauveau, Gradignan, France


Thursday, 28 May - 13:15-15:15
 

CME 14
 

Perspectives on renal stone disease: a 360° appraisal - A series of case-based presentations on renal stone disease
 

Genetics of calcium balance and hypercalciuria
Rajesh V. Thakker, Oxford, United Kingdom
Nephrology and Urology
Shabbir Moochhala, London, United Kingdom
Clinical Chemistry and renal stone disease
Gill Rumsby, London, United Kingdom
Marta Lapsley, London, United Kingdom
Urology and Nephrology
Pietro Manuel Ferraro, Rome, Italy


Thursday, 28 May - 13:15-15:15
 

CME 15
 

Exercise as Medicine in CKD
 

The new polypill - Exercise training in patients with CKD
Naomi Clyne, Lund, Sweden
Effects of exercise training on functional status and quality of life in CKD
Evangelia Kouidi, Thessaloniki, Greece
Wasting, nutrition and exercise training in CKD
Adamasco Cupisti, Pisa, Italy
Evaluation of functional status before and during exercise training
Pelagia Koufaki, Edinburgh, United Kingdom
Prescription of exercise training – practical aspects at different stages of CKD
Rolfdieter Krause, Berlin, Germany


Thursday, 28 May - 15:30-17:30
 

CME 16 - EuroPD Working Group
 

Advanced level clinical CME
 

Management of diabetics on PD
James Heaf, Bagsvaerd, Denmark
CKD-MBD in PD patients
Mario Cozzolino, Milano, Italy
Peritoneal dialysis for treatment of congestive heart failure
Speaker to be confirmed
Incompliance and adherence: can we change it?
Monika Lichodziejewska-Niemierko, Gdańsk, Poland


Thursday, 28 May - 15:30-17:30
 

CME 17
 

Current questions in clinical practice regarding AKI
 

Sense and nonsense of classifications of AKI
Wim Van Biesen, Ghent, Belgium
Assessment of volume status in patients at ICU
Jeroen Kooman, Maastricht, The Netherlands
Anticoagulation in AKI-RRT: where do we stand in 2015?
Speaker to be confirmed
Dosing regimens in patients with AKI on RRT
Andrew Lewington, Leeds, United Kingdom


Thursday, 28 May - 15:30-17:30
 

CME 18
 

The Lancet Workshop


Thursday, 28 May - 15:30-17:30
 

CME 19
 

Imaging in nephrology


Thursday, 28 May - 15:30-17:30
 

CME 20
 

Genetics and kidney disease for the beginners
 

Epigenetics in kidney disease
Gerjan Navis, Groningen, The Netherlands
Micro-RNAs and their importance in kidney disease
Ariela Benigni, Bergamo, Italy
Methodology of GWAS and its application to kidney disease
Carsten Boeger, Regensburg, Germany
Next generation sequencing for research and diagnostics of kidney disease
Nine V.A.M. Knoers, Utrecht, The Netherlands

 
  
SATELLITE MEETINGS
 
 
return to top